When will the patents on PLASMA-LYTE R IN PLASTIC CONTAINER expire, and when will generic PLASMA-LYTE R IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	PLASMA-LYTE R IN PLASTIC CONTAINER	calcium chloride; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium lactate	INJECTABLE;INJECTION	017438-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 25, 2026

PLASMA-LYTE R in a plastic container is a prescription intravenous electrolyte solution marketed by Baxter Healthcare Corporation. Its commercial value comes from recurring hospital demand for large-volume parenteral fluids, not from patent exclusivity or differentiated intellectual property. Baxter does not disclose product-level revenue for PLASMA-LYTE R, so its financial trajectory must be assessed through hospital utilization, IV-fluid shortages, manufacturing capacity, pricing, and Baxter’s broader Medical Products portfolio.

What is PLASMA-LYTE R in a plastic container?

PLASMA-LYTE R is a sterile, nonpyrogenic intravenous solution containing electrolytes and metabolizable anions. The product is supplied in a flexible plastic container and is administered in clinical settings requiring replacement of water and electrolytes.

The formulation includes:

Sodium chloride
Potassium chloride
Magnesium chloride
Sodium acetate
Sodium gluconate
Water for injection

The product does not contain calcium. That distinguishes it from Lactated Ringer’s and affects compatibility with certain drugs and blood products. The acetate and gluconate components are metabolized to bicarbonate under appropriate physiologic conditions.

The plastic container is a delivery and packaging attribute rather than a separate active pharmaceutical ingredient. Baxter’s VIAFLEX-style flexible containers are designed for single-use intravenous administration and are distributed through hospitals, wholesalers and group purchasing organizations.

What is the FDA regulatory status of PLASMA-LYTE R?

PLASMA-LYTE R is an FDA-approved prescription intravenous solution. It is regulated as a finished drug product rather than as a medical device or biologic.

Public FDA labeling identifies the product as an intravenous electrolyte replacement solution manufactured by Baxter Healthcare Corporation. The product’s regulatory value depends on maintaining compliance with:

Current good manufacturing practices
Sterility assurance requirements
Container-closure integrity
Extractables and leachables controls
Stability and shelf-life requirements
FDA drug shortage and supply reporting obligations

Because PLASMA-LYTE R is a sterile large-volume parenteral, manufacturing compliance is commercially important. A company may be able to reproduce the formulation, but building qualified sterile-fill capacity and securing reliable packaging supply presents a material entry barrier.

What is the Orange Book status of PLASMA-LYTE R?

PLASMA-LYTE R is an NDA-regulated prescription product. Its commercial position does not appear to depend on a conventional patent-protected small-molecule exclusivity period.

The Orange Book is relevant for identifying approved products, reference-listed-drug status and any listed patents or exclusivity. For an established electrolyte solution such as PLASMA-LYTE R, the principal barriers are usually manufacturing, regulatory approval, hospital contracting and supply reliability rather than active composition-of-matter patents. FDA’s Orange Book should be used for the current listing and any product-specific patent information.[1]

How many patents protect PLASMA-LYTE R?

No commercially significant, publicly identified patent estate is generally associated with the basic PLASMA-LYTE R electrolyte composition. The formulation contains long-established electrolytes and organic anions that are widely used in parenteral fluids.

Potentially relevant intellectual property categories include:

IP category	Relevance to PLASMA-LYTE R	Commercial impact
Composition-of-matter patent	Low for legacy electrolyte formulation	Low
Method-of-use patent	Limited for routine electrolyte replacement	Low
Container patent	Possible at the platform level	Low to moderate
Manufacturing process patent	Possible for specific filling or packaging processes	Moderate
Trade secret	Relevant to process controls and scale-up	Moderate
Trademark and product branding	Relevant to customer recognition	Moderate
Regulatory know-how	Relevant to sterile production and validation	High

The most durable protection is operational. A rival would need to replicate the formulation, demonstrate pharmaceutical equivalence where applicable, qualify a sterile production process, pass inspection and secure commercial distribution.

When does PLASMA-LYTE R lose exclusivity?

PLASMA-LYTE R is an established product and does not appear to have a meaningful remaining market exclusivity period comparable to a recently approved innovative drug. Any historical exclusivity period would have expired long before the current market cycle.

The relevant question is therefore not when PLASMA-LYTE R loses exclusivity. It is whether competitors can obtain approval and supply hospitals at commercially acceptable scale.

For a legacy intravenous solution, market entry can occur through:

An abbreviated new drug application where the regulatory pathway is available.
A new drug application for a formulation or presentation that does not fit the applicable generic pathway.
A product license or manufacturing arrangement involving an established sterile-injectable supplier.
Hospital or group-purchasing contracts that support private-label distribution.

What generic entry risks exist for PLASMA-LYTE R?

Generic entry risk is structurally high because the formulation is mature and the therapeutic category is well understood. Commercial entry risk is more complicated because sterile injectables have high fixed costs and a history of manufacturing interruptions.

The main generic-entry factors are:

Availability of validated sterile-fill capacity
Access to flexible plastic containers and overwrap materials
FDA inspection history
Ability to manufacture at large batch scale
Hospital formulary acceptance
Contracting with group purchasing organizations
Reliability during shortages
Pricing relative to Baxter’s branded product
Compatibility and labeling differences

A new competitor would not need to establish a novel clinical benefit. It would need to show that the product meets applicable quality, safety, sterility and performance requirements. The product’s low scientific complexity reduces development risk, while the sterile manufacturing requirement increases capital and execution risk.

Are there Paragraph IV challenges to PLASMA-LYTE R?

No prominent, commercially material Paragraph IV litigation campaign is associated with PLASMA-LYTE R in the public patent record. Paragraph IV litigation is generally more relevant to products protected by listed patents with meaningful remaining terms. A mature electrolyte solution with little apparent patent-based exclusivity has less incentive for a challenger to pursue a patent-invalidity strategy.

A competitor could still contest patents relating to a container, manufacturing process or specific formulation. Such a dispute would likely have narrower commercial scope than a composition-of-matter challenge involving a high-value branded drug.

What formulations are protected by PLASMA-LYTE R?

The product’s principal commercial protection is the combination of electrolyte concentrations, anion selection, sterility, container presentation and validated shelf life.

PLASMA-LYTE R should be distinguished from related products:

Product	Key formulation distinction	Competitive role
PLASMA-LYTE R	Balanced electrolyte solution with acetate and gluconate; no calcium	Direct or near-direct comparator
PLASMA-LYTE A	Related balanced crystalloid formulation	Baxter portfolio substitute or alternative
PLASMA-LYTE 148	Widely used balanced electrolyte solution with a different electrolyte profile	Major internal and external comparator
Lactated Ringer’s	Contains calcium and lactate	Broad hospital competitor
0.9% Sodium Chloride	Unbalanced isotonic saline without potassium, magnesium or organic anions	High-volume commodity substitute
Normosol-R	Balanced crystalloid competitor with related clinical positioning	Direct branded/commodity competitor

The presence or absence of calcium can influence drug compatibility and clinical selection. Hospitals may maintain more than one balanced crystalloid because different clinical departments use distinct protocols.

How does PLASMA-LYTE R compare with saline and Lactated Ringer’s?

PLASMA-LYTE R competes in a large but price-sensitive market for intravenous crystalloid solutions.

Versus 0.9% sodium chloride

Saline has the broadest clinical familiarity, substantial manufacturing capacity and extensive generic availability. Its low unit price creates a difficult benchmark for PLASMA-LYTE R. Balanced solutions may be preferred in some clinical settings because their electrolyte and anion profiles more closely approximate plasma, but purchasing decisions also depend on protocol, physician preference, inventory and contract price.

Versus Lactated Ringer’s

Lactated Ringer’s is a major alternative for fluid resuscitation and replacement. It contains calcium and lactate, while PLASMA-LYTE R uses acetate and gluconate and does not contain calcium. The distinction affects compatibility, clinical protocols and formulary design.

Versus other balanced crystalloids

PLASMA-LYTE R is most exposed to PLASMA-LYTE A, PLASMA-LYTE 148, Normosol-R and other balanced crystalloid products. Baxter can benefit from portfolio placement when hospitals standardize multiple formulations with one supplier, but internal products also compete for the same IV-fluid budget.

What drives the market for PLASMA-LYTE R?

The market is driven by utilization rather than innovation.

Hospital admissions and procedure volume

Demand rises with inpatient admissions, emergency-department activity, surgical procedures, trauma care, intensive-care treatment and ambulatory procedures requiring intravenous access.

IV-fluid shortages

Shortages can increase demand for alternative suppliers and elevate realized pricing. They can also create temporary substitution away from a product if manufacturing capacity is constrained. The FDA has repeatedly identified IV fluids as a shortage-sensitive category because production is concentrated among a limited number of manufacturers and facilities.[2]

Manufacturing concentration

Large-volume parenterals require specialized facilities, validated aseptic processes and high-throughput packaging. Facility outages, contamination events, hurricanes, transportation interruptions and raw-material shortages can affect national supply.

Hospital procurement

Purchasing is heavily influenced by group purchasing organizations, multiyear contracts, national accounts and supply guarantees. A product with no patent premium can still retain share if the supplier provides dependable delivery and a broad IV-fluid portfolio.

Pricing pressure

The underlying ingredients are inexpensive relative to the manufacturing, packaging, quality-control and distribution costs. Price competition is therefore strongest where multiple suppliers have reliable capacity. Shortages reverse that dynamic temporarily.

What is the financial trajectory for PLASMA-LYTE R?

Baxter does not report revenue, gross margin or operating profit for PLASMA-LYTE R separately. The product’s financial trajectory must therefore be inferred from the economics of Baxter’s IV-therapy portfolio and the broader large-volume parenteral market.

Financial factor	Expected effect on PLASMA-LYTE R
Stable hospital demand	Supports recurring base revenue
Product maturity	Limits premium pricing and growth from innovation
IV-fluid shortages	Can increase short-term volume or pricing
New sterile-injectable entrants	Creates long-term price pressure
Container and resin costs	Compress margins when input prices rise
Baxter manufacturing reliability	Directly affects shipments and share
GPO contracting	Supports volume but limits price flexibility
Portfolio bundling	Can protect account access
Regulatory remediation	Can reduce supply and increase cost
Clinical preference for balanced fluids	Supports mix, but does not guarantee price premium

The likely financial profile is a mature, recurring-revenue product with modest organic growth. Its value is greatest as part of a broader institutional IV-fluid portfolio. PLASMA-LYTE R is unlikely to be a standalone growth asset comparable to an innovative pharmaceutical product.

Baxter’s annual reports provide segment-level information, but they do not identify PLASMA-LYTE R revenue separately.[3] Product-level valuation should therefore use bottom-up assumptions for unit volume, average selling price, hospital account penetration and supply availability rather than reported brand revenue.

Which companies compete with PLASMA-LYTE R?

The competitive field includes manufacturers of balanced crystalloids, saline and other large-volume parenteral products.

Relevant competitors and substitutes include:

ICU Medical, including products historically associated with Hospira’s injectable portfolio
Fresenius Kabi
B. Braun
Pfizer, through selected injectable and IV-fluid products
Baxter’s own PLASMA-LYTE variants
Regional generic injectable manufacturers
Private-label suppliers serving hospitals and group purchasing organizations

Competition is not limited to identical formulations. Hospitals frequently evaluate products at the category level, allowing saline, Lactated Ringer’s and balanced crystalloids to compete for the same institutional budget.

What manufacturing and IP barriers affect market entry?

Manufacturing is the principal barrier.

A prospective entrant must establish:

Sterile compounding and filling
Validated container-closure systems
Container compatibility and integrity
Endotoxin and particulate controls
Stability data
High-volume packaging capability
Reliable raw-material procurement
FDA-compliant quality systems
National distribution and inventory reserves

Plastic packaging can create separate technical requirements involving permeability, extractables, leachables, seal integrity and overwrap performance. These requirements do not create the same exclusivity as a pharmaceutical patent, but they increase development cost and delay.

The strongest defensible asset is often a reliable supply network. During a shortage, hospitals may favor an established supplier even when alternative products are legally available.

What litigation and settlement agreements affect PLASMA-LYTE R?

No major publicly recognized patent litigation or settlement agreement appears to determine the current market position of PLASMA-LYTE R. The product’s competitive risks are operational and commercial rather than litigation-driven.

Relevant disputes, if they arise, would more likely involve:

Product liability
Manufacturing quality
Contract performance
Hospital procurement
Container technology
Regulatory compliance
Supply interruption

Those issues differ from the patent settlements commonly seen for high-revenue oral drugs.

What is the geographic coverage of PLASMA-LYTE R?

Baxter has an international hospital presence, but product names, formulations, container presentations, regulatory approvals and package sizes vary by jurisdiction. U.S. PLASMA-LYTE R status should not be assumed to establish equivalent approval in Europe, Canada, Asia-Pacific or Latin America.

Geographic expansion depends on:

Local registration
Pharmacopoeial requirements
Country-specific labeling
Hospital procurement systems
Local sterile manufacturing or import authorization
Cold-chain and distribution requirements where applicable
National reimbursement and tender pricing

The U.S. market is commercially important because of its large hospital system and high IV-fluid utilization, but supply interruptions can rapidly affect global allocation.

Key Takeaways

PLASMA-LYTE R is a mature Baxter intravenous electrolyte solution supplied in a flexible plastic container.
Its commercial value comes from recurring hospital use, not meaningful remaining patent exclusivity.
No major Paragraph IV challenge, patent litigation campaign or settlement agreement appears to define the product’s current market position.
The primary competitive threats are saline, Lactated Ringer’s, other balanced crystalloids and new sterile-injectable suppliers.
Manufacturing capacity, sterility assurance, container technology and supply reliability are stronger barriers than composition patents.
Baxter does not disclose product-level PLASMA-LYTE R revenue, preventing a standalone revenue or margin calculation from public filings.
The expected financial profile is mature and recurring, with temporary upside during shortages and long-term pressure from generic competition and hospital contracting.
The product’s strategic value is higher as part of Baxter’s broader IV-fluid portfolio than as an isolated pharmaceutical asset.

FAQs About PLASMA-LYTE R

Is PLASMA-LYTE R a generic drug?

PLASMA-LYTE R is an established prescription intravenous solution. Its formulation is mature and subject to generic or multisource competition, although the exact regulatory pathway depends on the formulation, presentation and FDA reference-product status.

Does PLASMA-LYTE R contain calcium?

No. PLASMA-LYTE R does not contain calcium. This differentiates it from Lactated Ringer’s and can affect drug compatibility and clinical selection.

Is PLASMA-LYTE R the same as PLASMA-LYTE A?

No. PLASMA-LYTE R and PLASMA-LYTE A are related balanced crystalloid products, but their electrolyte and anion compositions are not identical. They should be evaluated by formulation and labeling rather than treated as interchangeable by name.

Can a hospital substitute normal saline for PLASMA-LYTE R?

Clinical substitution depends on the intended use, institutional protocol, physician direction, patient condition and drug compatibility. Normal saline is a major alternative, but it is not compositionally identical to PLASMA-LYTE R.

Is PLASMA-LYTE R a high-growth pharmaceutical product?

No. It is best characterized as a mature hospital-support product with recurring demand. Growth is tied to hospital utilization, balanced-crystalloid adoption, supply availability and pricing rather than new clinical indications.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
Baxter International Inc. (2024). Annual report. https://www.baxter.com/investors/financial-information/annual-reports
Baxter Healthcare Corporation. (n.d.). PLASMA-LYTE R Injection, USP prescribing information. U.S. Food and Drug Administration labeling database. https://dailymed.nlm.nih.gov/ dailymed/

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	PLASMA-LYTE R IN PLASTIC CONTAINER at DailyMed

PLASMA-LYTE R IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Plasma-lyte R In Plastic Container, and when can generic versions of Plasma-lyte R In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for PLASMA-LYTE R IN PLASTIC CONTAINER

US Patents and Regulatory Information for PLASMA-LYTE R IN PLASTIC CONTAINER

PLASMA-LYTE R in Plastic Container: Market Dynamics, Financial Trajectory, Patents, and Competitive Position